New combo therapy aims to slow pancreatic cancer progression
NCT ID NCT05494697
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests whether adding the drug Ampligen to standard treatment can help people with locally advanced pancreatic cancer live longer without their disease getting worse. About 90 adults who have already completed at least four months of first-line therapy without progression will be randomly assigned to receive either Ampligen plus standard care or standard care alone. The main goal is to see if the combination delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.